Trial Profile
A trial comparing the pharmacokinetic properties of fast-acting insulin aspart between children, adolescents and adults with type 1 diabetes
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Aug 2018
Price :
$35
*
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 10 Jul 2018 Status changed from recruiting to completed.
- 31 Oct 2017 New trial record